CTLA4 and cancer: Immune modulating antibodies or checkpoint inhibitors most commonly target the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) or PD-1/PD-L1 ligand as the cancer cells display these ligands on their cell surface.